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INTRODUCTION
Human esophageal carcinosarcomas are uncom-
mon malignant tumors that have a characteristic
gross polypoid configuration and contain carcinoma-
tous and sarcomatous component. Spindle cell car-
cinoma (so-called carcinosarcoma) is composed of
squamous cell carcinoma and sarcomatous spindle
cells that are derived from metaplasia of the carci-
noma cells (1).
The vascular endothelial growth factor (VEGF) is
a highly specific mitogen for vascular endothelial
cells, its expression is induced by hypoxia, oncogene
activation, and various cytokines. VEGF is impor-
tant in angiogenesis and the neovascularization of
solid tumor growth (2). Expression of VEGFs and
VEGFRs in the esophageal so-called carcinosarcoma
has not been fully undestood, although Kato et. al.
reported that VEGF expression in the esophageal
cancers is correlated with a poor prognosis (3). It
is very important to investigate the expression of
VEGFs and their receptors in clinically. The VEGF
family members VEGF-A,-B,-C, and -D have been
identified (4) of which VEGF-A is the most potent
promoter of angiogenesis. Six VEGF-A isoforms,
consisting of 121, 145, 165, 183, 189, or 206 amino
acids, are generated as a result of alternative splic-
ing from a single gene (5). The 121 and 165 iso-
forms are usually the predominant forms. VEGF121
is more angiogenic and tumorigenic than the other
isoforms (5). VEGFs bind to three receptor pro-
tein tyrosine kinases, VEGF-R1 (Flt-1), VEGF-R2
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(KDR/Flk-1), and VEGF-R3 (Flt-4) (4). VEGF-R2
which is a VEGF-A receptor plays an important role
in pathological neovascularization via its tyrosine
kinase activity and growth promoting signals to
blood vessels (4). VEGF-R3 interacts with VEGF-C
and is involved in lymphangiogenesis (4).
We have established a novel human cell line from
a metastatic esophageal so-called carcinosarcoma.
HN-Eso-1 is, to our knowledge, the only such cell
line in existence. It is very important to estimate the
biological aspects in the HN-Eso-1. We have dem-
onstrated that VEGF plays an important role in pro-
tecting HN-Eso-1 cells from the anti-tumor agent
cisplatin.
MATERIALS AND METHODS
Establishment of the HN-Eso-1 cell line
Tumor tissue was obtained from the metastatic
adrenal gland of the esophageal so-called carcino-
sarcoma in 2002, and the informed consent was ob-
tained from the patient. Tumor tissue was cut thor-
oughly by the scalpel and cultured in Dulbecco’s
Modified Eagles Medium (DMEM) containing 8%
fetal bovine serum (FBS) with penisilin and strep-
tomycin on the dish. After 4 weeks, each colony was
moved to a 96-well plate. HN-Eso-1 cells were es-
tablished from one of the colonies and have been
cultured for 2 years.
Cell culture
DLD-1 (colon adenocarcinoma), SW480 (colon
adenocarcinoma), and Lovo (colon adenocarcinoma)
cells were a kind gift from Dr. Ryoko Suzuki (Kochi
Medical School). They were cultured in DMEM
containing 8% FBS as described above.
Reagents
Cisplatin was purchased from Kyowa Hakko
(Tokyo Japan). VEGF165 was purchased from
PeproTech EC (London UK). Anti-VEGF antibody
(A-20) was obtained from Santa Cruz Biotechnology
(Los Angeles, CA, USA).
Isolation and detection of VEGF and VEGFR mRNA
1106 cells were seeded on 6-cm dishes and in-
cubated for 24 hours. Cells were washed twice in
ice-cold phosphate-buffered saline (PBS) and the
total cellular RNA isolated using the TRIZOL re-
agent (Gibco-BRL) according to the manufacturer’s
protocol. Specific mRNA was assayed using reverse
transcription polymerase chain reaction (RT-PCR).
PCR conditions : VEGF-A : denaturing, 94for 1
min, annealing, 60for 1 min and elongation, 72
for 1 min, for 30 cycles ; VEGF-B : denaturing, 94
for 1 min, annealing, 60for 1 min and elongation,
72for 1 min, for 30 cycles ; VEGF-C : denatur-
ing, 94for 1 min, annealing, 60for 1 min and
elongation, 72for 1 min, for 30 cycles ; VEGF-D
denaturing, 94for 1 min, annealing, 60for 1
min and elongation, 72for 1 min, for 30 cycles ;
VEGFR-1 : denaturing, 94for 1 min, annealing,
60for 1 min and elongation, 72for 1 min, for
30 cycles ; VEGFR-2 : denaturing, 94for 1 min,
annealing, 60for 1 min and elongation, 72for
1 min, for 30 cycles ; VEGFR-3 : denaturing, 94
for 1 min, annealing, 60for 1 min and elongation,
72for 1 min, for 30 cycles ; Beta-actin : denatur-
ing, 94for 30 s, annealing, 50for 40 s and elon-
gation, 72for 1 min, for 30 cycles ; and final elon-
gation at 72for 10 min-1 cycle. PCR products
were subjected electrophoresis in 2% agarose gel.
The primer sequences were VEGF-A sense : 5’ -
CGAAGTGGTGAAGTTCATGGATG-3’ ; VEGF-A
antisense : 5’ -TTCTGTATCAGTCTTTCCTGGTGA-
3’ ; VEGF-B sense : ACATCACCCATCCCACTCC-
AGGCTCCTTTGTTCCCCCACT-3’, VEGF-B an-
tisense : 5’ -GCTCCTTTGTTCCCCCACT-3’, VEGF-
C sense : 5’ -TGTTTTCCTCGGATGCTGGAG-3’,
VEGF-C antisense : 5’ -TGGGGCAGGTTCTTTTA-
CATACAC-3’, VEGF-D sense : 5’ -CCACTTGCTG-
GAACAGAAGACCAC-3’, VEGF-D antisense : 5’ -
ATGACAGGGATGGGGAACTTGG-3’, VEGFR-1
sense : 5’ -GCACCTTGGTTGCTG-3’, VEGFR-1 an-
tisense : CGTGCTGCTTCCTGGTCC-3’, VEGFR-2
sense : 5’ -CTGGCATGGTCTTCTGTGAAGCA-3’,
VEGFR-2 antisense : 5’ -AATACCAGTGGATGTG-
ATGCGG-3’, VEGFR-3 sense : 5’ -CAGGTGCCT-
TCCCAGACACTGGCGTTACT-3’, VEGFR-3 an-
tisense : 5’ -ACTCATATTACCAAGGAATAACTGG-
CGGGCA-3’, beta-actin sense : 5’ -ATTGGCAATG-
AGCGGTTCCGC-3’ ; beta-actin antisense : 5’ -CT-
CCTGCTTGCTGATCCACATC-3’, as previously de-
scribed (4, 6).
Western blotting
We performed Western blotting as previously de-
scribed (6-9). 4106 cells were seeded on a 10-cm
dish for 24 hours. Cells were washed with PBS and
lysed in RIPA buffer (Upstate Biotechnology Inc.,
NY, USA) containing 20 mM sodiumpyrophosphate,
20 mM NaF, 1 mM orthovanadate, 2 mM pyrophos-
phate, 1 mM PMSF, 10 μg/ml aprotinin, and 10 μg/
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ml leupeptin. Cell lysates containing comparable
amounts of proteins, estimated by a Bradford assay
(Bio-Rad, Munchen, Germany) were separated by
SDS-PAGE and subjected to Western blotting.
3,-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide (MTT) assay to determine cell vi-
ability
The MTT assay was performed as previously de-
scribed (6, 9). In a 96-well plate, 1104 cells/100 μl
of cell suspension were used to seed each well.
After 24 h, reagents (cisplatin and/or VEGF) were
added to each well and the cells were incubated for
24 h. After 24 h incubation with/without reagents,
10 μl of a 2.5 mg/ml solution of MTT in PBS was
added to each well and incubated for 2 hours at
37. The resulting violet formazan precipitate was
solubilized by the addition of 100 μl of a 50% N,N,-
dimethyl formamide/10% SDS solution, and incu-
bated for 6 hours at room temperature. The plate
was then analyzed on a plate reader at 570 nm to
measure sample absorbances.
Microscopic analysis
Cells were seeded and cultured on the covered
glass in the dish for 24 h and then covered glass
were washed twice with PBS and fixed with 100%
ethanol. Hematoxylin and eosine (H&E) staining
was done and electron microscopic analysis was
performed as previously described.
RESULT
RT-PCR
RT-PCR was performed as described in the ma-
terials and methods section and the results are
shown in Fig. 1. VEGF-A was expressed more in
HN-Eso-1 than in the SW480, DLD-1, or Lovo cell
lines. We previously revealed that VEGF in DLD-1
was detected in 35 cycles of PCR (6) . VEGF -C
was detected only in HN-Eso -1, while VEGF -D
was detected in SW480, Lovo, and HN-Eso-1 cells.
VEGFR-1 was detected in all four cell lines. VEGFR-
2 was detected in SW480 and HN-Eso-1 only. We
could not detect the transcription of VEGF-B or
VEGFR-3 in any cell line.
Expression of VEGF in the HN-Eso-1
Expression of VEGF was estimated by Western
blotting (Fig. 2). VEGF was expressed in all cell
lines, but most strongly in HN-Eso-1 and Lovo cells.
Cell viability
We tested whether VEGF could protect HN-Eso-
1 cells from the anti-tumor agent, cisplatin. Cisplatin
reduced the viability of HN-Eso-1 cells in a dose-
dependent fashion as shown in Fig. 3 (lane2 - 5).
The percent of cell viabilitystandard deviation
(S.D.) was described as follows ; 686.44% (0.5 μg/
ml), 65.22.86% (1 μg/ml), 63.23.45% (2 μg/ml),
Figure 2. Expression of VEGF
30 μg protein was loaded in each lane. Lane 1, SW480 ; 2, DLD-
1 ; 3, HN-Eso-1 ; 4, Lovo cells
Figure 1. RT-PCR
VEGF-A (VEGF121, VEGF165), VEGF-C, VEGF-D, VEGFR-1,
and VEGFR-2 were detected by RT-PCR. Lane 1, SW480 ; 2,
Lovo ; 3, DLD-1 ; 4, HN-Eso-1 cells
Figure 3. Assessment of cell viability
Cell viability was determined by MTT assay. Results were indu-
cated as % of cell viabilitystandard deviation (S.D.). Triplicate
experiments were performed. Treatment : 1 ; none, 2 ; cisplatin
0.5 μg/ml, 3 ; Cisplatin 1 μg/ml, 4 ; Cisplatin 2 μg/ml, 5 ; Cis-
platin 5 μg/ml, 6 ; VEGF (10 ng/ml)+Cisplatin 0.5 μg/ml, 7 ;
VEGF (10 ng/ml)+Cisplatin 1 μg/ml, 8 ; VEGF (10 ng/ml)+
Cisplatin 2 μg/ml, 9 ; VEGF (10 ng/ml)+Cisplatin 5 μg/ml, 10 ;
VEGF (100 ng/ml)+Cisplatin 0.5 μg/ml, 11 ; VEGF (100 ng/
ml)+Cisplatin 1 μg/ml, 12 ; VEGF (100 ng/ml)+Cisplatin 2 μg/
ml, 13 ; VEGF (100 ng/ml)+Cisplatin 5 μg/ml
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301.23% (5 μg/ml). In the case of combination
with VEGF (10 or 100 ng/ml), effect of cisplatin was
attenuated. Results were described as follows ; 76.4
2.91% (cisplatin 0.5 μg/ml and VEGF 10 ng/ml),
68.80.61% (cisplatin 1 μg/ml and VEGF 10 ng/
ml), 67.82.88% (cisplatin 2 μg/ml and VEGF 10
ng/ml), 49.15.57% (cisplatin 5 μg/ml and VEGF
10 ng/ml), 96.62.2% (cisplatin 0.5 μg/ml and
VEGF 100 ng/ml), 72.21.28% (cisplatin 1 μg/ml
and VEGF 100 ng/ml), 73.72.56% (cisplatin 2 μg/
ml and VEGF 100 ng/ml), 711.69% (cisplatin 5
μg/ml and VEGF 100 ng/ml).
Microscopic analysis
HN-Eso-1 cells are epithelial cell shape and they
have a large nuclei and were developed mitochon-
dria (Fig. 4). The mitotic cells were shown in Fig.
4 A.
DISCUSSION
We have established the novel HN-Eso-1 cell line
from the esophageal so-called carcinosarcoma and
used RT-PCR analysis to examine the VEGFs and
VEGFRs in cells.
VEGF is a highly specific mitogen for vascular en-
dothelial cells that is induced by hypoxia, oncogene
activation, and variety of cytokines. VEGF is impor-
tant in angiogenesis and neovascularization of solid
tumor growth. Expression of VEGF and VEGFRs
in the esophageal so-called carcinosarcoma has not
been fully understood. It is very important to investi-
gate the role of expression of VEGF and VEGFRs
in the esophageal so-called carcinosarcoma. In these
cells, transcription of VEGF-A, C, D, VEGFR-1, and
VEGFR-2 were detected (Fig. 1). Expression of
VEGF (VEGF-A) was detected in HN-Eso-1 cells
(Fig. 2) and the other cell lines, Lovo, SW480, and
DLD-1 also expressed VEGF (Fig. 2). VEGF-R2,
which is a VEGF-A receptor plays an important role
in pathological neovascularization via its tyrosine
kinase activity and growth promoting signals to
blood vessels (4). These results suggest that ex-
pression of VEGFs and VEGFRs might be impli-
cated not only in the HN-Eso-1 autocrine system
but also in promotion of tumor environment. Indeed,
the pathological analysis in a sample tissue suggests
that both angiogenesis and lymphangiogenesis was
well developed (data not shown).
Next we evaluated the effect of VEGF on HN-
Eso-1 cells, although its direct effect on cancer cells
has not been fully understood. Recombinant VEGF
attenuated the cytotoxic effect of cisplatin on HN-
Eso-1 cells (Fig. 3). However VEGF could not res-
cue the cell death of SW480, DLD-1, or Lovo treated
with cisplatin. (data not shown) VEGF appears to
play an important role in the cytoprotective effect
on HN-Eso-1 cells against anti-cancer agents.
SU11248, a VEGFR-2 inhibitor, has been ap-
proved for cancer therapy, and undergone clinical
setting (10). Our results suggest that SU11248
could be useful of esophageal so-called carcinosar-
coma, in combination with other anti-cancer agents.
Further studies are required to investigate in detail
the cell survival signals of HN-Eso-1.
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